India SEBI Eases Rules for Global Funds Buying Sovereign Bonds
India's securities market regulator on Wednesday relaxed certain rules for foreign funds investing in local government bonds, to increase participation from funds tracking global bond indexes.
Existing and new funds that exclusively invest in government securities under the Fully Accessible Route or FAR will not be required to furnish investor group details, the regulator said in a statement after its board meeting in Mumbai.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
2 days ago
- Miami Herald
Detroit Big 3 benefit from auto tariffs now, but time is running out
U.S. tariffs are taking a toll on Japan's economy. Exports from the Far-East island nation fell in May for the first time in eight months, mainly due to declines from stalwarts like Toyota, Nissan, and Mitsubishi. Autos accounted for about 28% of Japan's total 21 trillion yen ($145 billion) of export goods in 2024. So when exports to the U.S. fell 11.1% in May, you can bet a lack of cars leaving the Nagoya port played a big role. Related: Toyota makes surprising move to beat Tesla in key market According to government data, total exports declined 1.7% year over year by value to 8.1 trillion yen. While the decline was felt, it was much better than the median 3.8% decline analysts expected after exports rose 2% in April. U.S.-bound automobile exports fell nearly 4%. "The value of automobile exports to the U.S. fell, but their volume did not drop that much," Daiwa Institute of Research economist Koki Akimoto told Reuters. "This indicates Japanese automakers are effectively shouldering the tariff costs and not charging customers." Meanwhile, U.S. automakers have taken advantage of the situation, leveraging their domestic manufacturing footprints to offer incentives. While Ford, Stellantis, and General Motors have all said that tariffs will shave billions from their EBITDAs this year, they are still in a better position than the Japanese automakers, who, after dominating the U.S. market for decades, now have to pay 25% duties. U.S. auto dealers, including those with Japanese brand names, have actually benefited over the short term from tariffs. Dealers have a front-line view of the U.S. auto market, which appears to be at an inflection point," said Cox Automotive Chief Economist Jonathan Smoke last month. "The recent sales pace has been a positive, lifting current market sentiment higher for franchised dealers." Buyers have been motivated by the threat of tariffs raising prices in the coming weeks. And sellers have been fueling that demand with incentives. Ford, for instance, has been running its "From America, For America" campaign to provide customers with employee pricing. Related: Car buyers should shop these brands for the best tariff deal "It's really paid off for us in the last 60 days. You've seen a lot of the results in the market. Last month (May)...we actually posted a 14.7% share here in the U.S. That's up 1.9 points of share on a year-over-year basis. A lot of times in this industry we fight for tenths of share, and to have a 1.9% increase year over year was very strong," said Ford Blue and Model e President Andrew Frick. In March, Japan Automobile Manufacturers Association (JAMA) Chairman Masanori Katayama said, "We will be looking at how to absorb short-term shocks and what concrete measures we can take to deal with these shocks, as well as how to deal with them in an all-Japan manner. On June 17, Prime Minister Shigeru Ishiba said following the G7 summit that Japan had yet to reach a deal with the U.S. on a tariff agreement. With a July 9 deadline for 24% tariffs looming, Japan may become more motivated to strike a deal soon. This means the slim advantage tariffs have given U.S. automakers may also soon be going away. Auto sales have climbed sharply in recent months as consumers were motivated by the incentives and the need to buy vehicles before any tariff-related price increases. But Bank of America is now saying that the growth it saw in consumer vehicle loan applications has declined from its peak in April, "suggesting that 'buying ahead' has largely run its course." More on carmakers: Popular Ford newcomer overtakes Jeep in a key areaJeep, Dodge parent has no solution for this emerging problemGeneral Motors makes $4 billion tariff move Bank of America expects lower-income and younger buyers to feel the most pain, as its data shows that median car payments have grown faster than new and used car prices since 2019. Shockingly, of those households with a monthly car payment, 20% have a payment over $1,000. In addition to capping your car payments at about 15% of your monthly take-home, financial experts also recommend shoppers aim for a 20% down payment, a 36- to 48-month loan term, and expenses (including insurance) at between 8% and 10% of your gross monthly income. Experts also recommend that you know your credit score and loan approval amount in advance and that you shop around with different lenders for the best rate. Related: Car buyers should be nervous about this emerging trend The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Bloomberg
2 days ago
- Bloomberg
India SEBI Eases Rules for Global Funds Buying Sovereign Bonds
India's securities market regulator on Wednesday relaxed certain rules for foreign funds investing in local government bonds, to increase participation from funds tracking global bond indexes. Existing and new funds that exclusively invest in government securities under the Fully Accessible Route or FAR will not be required to furnish investor group details, the regulator said in a statement after its board meeting in Mumbai.
Associated Press
11-06-2025
- Associated Press
Capstan Therapeutics Announces Initiation of Phase 1 Trial of Lead In Vivo CAR-T Therapy, CPTX2309, for Treating Autoimmune Disease
SAN DIEGO--(BUSINESS WIRE)--Jun 11, 2025-- Capstan Therapeutics, Inc. ('Capstan'), a clinical-stage biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced successful dosing of the first participants in its Phase 1 trial of CPTX2309, Capstan's lead anti-CD19 in vivo CAR-T candidate, for the treatment of B cell-mediated autoimmune disorders. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic activity (i.e., peripheral B cell depletion and recovery) of CPTX2309 treatment in healthy volunteers at various dose levels. Preclinical studies demonstrated rapid, deep, and transient B cell depletion in blood and tissues, which supported the clinical evaluation of CPTX2309 at the planned dose levels and regimens. 'With CPTX2309, our therapeutic goal is to achieve immune reset through rapid and profound B cell depletion using a transient, tunable, and fully off-the-shelf in vivo CAR-T technology,' said Ramin Farzaneh-Far, M.D., Chief Medical Officer at Capstan. 'The focus on a Phase 1 healthy volunteer population allows us to dose escalate efficiently, and importantly, underscores the potential safety advantages of an approach that does not involve lymphodepletion or permanent CAR integration into the genome. The objective of this trial is to determine a pharmacologically active dose (or doses) that can be advanced into Phase 2 studies to treat patients with autoimmune disease.' About Capstan Therapeutics, Inc. ( ) Capstan is a clinical-stage biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody, that deliver an RNA payload capable of reprogramming cells in vivo. Capstan's initial focus is on developing in vivo CAR-T therapies designed to combine the potency of CAR-T therapy with the convenience of an off-the-shelf product for the treatment of autoimmune diseases. For more information, please visit and follow us on LinkedIn. About CPTX2309 CPTX2309 is an investigational in vivo CAR-T therapy designed to target B cell-mediated autoimmune disorders through tunable and dose-dependent levels of CAR expression with a potentially favorable clinical safety profile. Preclinical data have shown that CPTX2309 demonstrates robust in vivo engineering of CD8+ CAR T cells, profound B cell depletion in blood and tissues, and repopulation with predominantly naïve B cells in non-human primates. Capstan is currently conducting a Phase 1 trial for CPTX2309 in healthy volunteers in Australia. View source version on CONTACT: Investors: Miguel Arcinas Senior Vice President of Corporate Development Capstan Therapeutics, Inc. [email protected]: Rhiannon Jeselonis Ten Bridge Communications [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: RESEARCH GENETICS CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY HEALTH PHARMACEUTICAL GENERAL HEALTH SCIENCE SOURCE: Capstan Therapeutics, Inc. Copyright Business Wire 2025. PUB: 06/11/2025 07:30 AM/DISC: 06/11/2025 07:28 AM
